Compounds > tert-butyl glycidyl ether
Page last updated: 2024-12-06

tert-butyl glycidyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

tert-Butyl glycidyl ether (TBGE) is an organic compound with the formula (CH3)3COCH2CHCH2O. It is a colorless liquid that is used as a solvent and as an intermediate in the production of other chemicals. TBGE is synthesized by the reaction of tert-butanol with epichlorohydrin. TBGE is known to be a skin irritant and can cause eye irritation. It is important to handle TBGE with caution and to wear appropriate protective equipment. TBGE is studied for its potential use as a monomer in the production of polymers and resins. It is also being investigated for its potential use in the synthesis of pharmaceuticals and other biologically active compounds.'

Cross-References

ID SourceID
PubMed CID24314
CHEMBL ID1569413
SCHEMBL ID93565
MeSH IDM0110818

Synonyms (65)

Synonym
AKOS009031522
tert-butyl glycidyl ether
(tert-butoxymethyl)oxirane
7665-72-7
NCGC00091765-01
t-butyl glycidyl ether
brn 0103483
butyl glycidyl ether, tert-
2,3-epoxypropyl-t-butyl ether
einecs 231-640-0
1,1-dimethylethyl glycidyl ether
propane, 1-tert-butoxy-2,3-epoxy-
t-bge
ccris 2632
oxirane, ((1,1-dimethylethoxy)methyl)-
tert-butyl glycidyl ether, 99%
2-(tert-butoxymethyl)oxirane
oxirane, [(1,1-dimethylethoxy)methyl]-
B1840 ,
1-tert-butoxy-2,3-epoxypropane
smr001372027
MLS002454450
2-[(2-methylpropan-2-yl)oxymethyl]oxirane
FT-0694173
sfjrujuemvazlm-uhfffaoysa-
inchi=1/c7h14o2/c1-7(2,3)9-5-6-4-8-6/h6h,4-5h2,1-3h3
NCGC00091765-02
HMS3039K14
NCGC00257807-01
dtxsid4024692 ,
tox21_200253
dtxcid104692
cas-7665-72-7
oxirane, 2-((1,1-dimethylethoxy)methyl)-
35f8x83d0g ,
unii-35f8x83d0g
SCHEMBL93565
2-tert-butoxymethyl-oxirane
t-butylglycidyl ether
rac tert-butyl glycidyl ether
glycidyl-tert-butyl ether
2-tert-butoxymethyloxirane
((1,1-dimethylethoxy)methyl)oxirane
2-(tert-butoxymethyl)oxirane #
glycidyl tert-butyl ether
ageflex tbge
CHEMBL1569413
tert-butylglycidylether
W-110231
(+/-)-tert-butylglycidyl ether
3-tert-butoxy-1,2-epoxypropane
tert-butyl 2,3-epoxypropyl ether
tert-butyl glycidyl ether, (+/-)-
2-trimethylmethoxymethyloxirane
p-tert-butyl glycidyl ether
2,3-epoxypropyl-tert-butyl ether
mfcd00010050
FT-0771546
CS-0204793
Q27256462
D88868
BS-23854
2-[(tert-butoxy)methyl]oxirane
EN300-20743
Z104480846

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" These agents demonstrate similar dose-response relationships over the range of concentrations up to 333 micrograms/ml."( Unscheduled DNA synthesis induced in human lymphocytes by butyl glycidyl ethers.
Frost, AF; Legator, MS, 1982)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency47.30790.047349.480674.9780AID651758
GLI family zinc finger 3Homo sapiens (human)Potency7.06170.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency49.99330.000221.22318,912.5098AID743040
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency50.11870.001024.504861.6448AID588535
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.004519.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency79.23400.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency54.49370.000627.21521,122.0200AID651741; AID720636
gemininHomo sapiens (human)Potency2.05730.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's5 (55.56)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.40 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		2.1510alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
allyl glycidyl ether
[no description available]		2.5220
n-butyl glycidyl ether
n-butyl glycidyl ether: structure		1.9610
thiolactic acid
thiolactic acid: RN given refers to parent cpd		2.110mercaptopropanoic acid
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510